Not Yet RecruitingNot Applicable

OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE

20 participantsStarted 2026-06-01

Plain-language summary

The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).

Who can participate

Age range5 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Children 5-18 years with SCD at steady state. Steady state will be defined as not requiring an acute care visit for pain in the last 28 days. Exclusion Criteria: * current use of antibiotics except prophylactic penicillin * current use of pre-or probiotic supplements * current use of PPI therapy * pregnant or lactating females * individuals with known allergy to Flaxseed

What they're measuring

Feasibility

Timeframe: 4 weeks

Trial details

NCT IDNCT07530965

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Chinenye R Dike, MD MS

205 638 9918 cdike@uabmc.edu

View on ClinicalTrials.gov More Sickle Cell Disease (SCD) trials